Corcept Therapeutics (HTD) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HTD Analyst Ratings

Moderate Buy

4 Buy

0 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Corcept

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HTD Stock 12 Month Forecast

Average Price Target

€107.04

▲(29.18% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is €107.04 with a high forecast of €144.06 and a low forecast of €43.65. The average price target represents a 29.18% change from the last price of €82.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"€28","145":"€145","57.25":"€57.3","86.5":"€86.5","115.75":"€115.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":144.05661765,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€144.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107.03843226599999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€107.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.6535205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,57.25,86.5,115.75,145],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.2,80.49666289615385,85.7933257923077,91.08998868846155,96.38665158461538,101.68331448076924,106.97997737692307,112.27664027307692,117.57330316923077,122.86996606538462,128.16662896153846,133.4632918576923,138.75995475384616,{"y":144.05661765,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.2,77.6491101743077,80.09822034861538,82.54733052292308,84.99644069723077,87.44555087153846,89.89466104584615,92.34377122015384,94.79288139446153,97.24199156876922,99.69110174307691,102.1402119173846,104.5893220916923,{"y":107.03843226599999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.2,72.77334773076923,70.34669546153846,67.9200431923077,65.49339092307693,63.06673865384616,60.64008638461539,58.213434115384615,55.78678184615384,53.36012957692308,50.93347730769231,48.50682503846154,46.08017276923077,{"y":43.6535205,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.72,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.87,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€144.06

Average Price Target€107.04

Lowest Price Target€43.65

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Nash

Canaccord Genuity

€130.96→€140.56

Buy

69.64%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Kiniksa Pharmaceuticals (NASDAQ: KNSA) and Medios AG (Other OTC: MEDOF)

David Amsellem

Piper Sandler

€76.83→€144.06

Buy

73.86%

Upside

Reiterated

07/30/26

Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

Swayampakula Ramakanth

H.C. Wainwright

€82.94→€144.06

Buy

73.86%

Upside

Reiterated

07/30/26

Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright

Kalpit Patel

Wolfe Research

€43.65

Sell

-47.32%

Downside

Reiterated

07/29/26

Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged

Ashwani Verma

UBS

€62.86

Buy

-24.14%

Downside

Upgraded

05/13/26

Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top NA Picks

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Nash

Canaccord Genuity

€130.96→€140.56

Buy

69.64%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Kiniksa Pharmaceuticals (NASDAQ: KNSA) and Medios AG (Other OTC: MEDOF)

David Amsellem

Piper Sandler

€76.83→€144.06

Buy

73.86%

Upside

Reiterated

07/30/26

Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

Swayampakula Ramakanth

H.C. Wainwright

€82.94→€144.06

Buy

73.86%

Upside

Reiterated

07/30/26

Corcept Therapeutics price target raised to $165 from $95 at H.C. WainwrightCorcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright

Kalpit Patel

Wolfe Research

€43.65

Sell

-47.32%

Downside

Reiterated

07/29/26

Corcept: Strong Lifyorli Launch But Legal and Regulatory Risks Keep Sell Rating and $50 Price Target Unchanged

Ashwani Verma

UBS

€62.86

Buy

-24.14%

Downside

Upgraded

05/13/26

Corcept Therapeutics upgraded to Buy from Neutral at UBSCorcept Therapeutics upgraded to Buy from Neutral at UBS

Joon Lee

Truist Financial

―

Buy

―

Reiterated

03/02/26

Wall Street Analysts Are Bullish on Top NA Picks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months

Swayampakula RamakanthH.C. Wainwright

Success Rate

15/19 ratings generated profit

Average Return

+21.54%

Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +21.54% per trade.

1 Year

Swayampakula RamakanthH.C. Wainwright

Success Rate

16/19 ratings generated profit

Average Return

+71.06%

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +71.06% per trade.

2 Years

Joon LeeTruist Financial

Success Rate

22/22 ratings generated profit

Average Return

+76.95%

Copying Joon Lee's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +76.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HTD Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HTD has received 13 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. HTD average Analyst price target in the past 3 months is 107.04.

Each month's total comprises the sum of three months' worth of ratings.

HTD Financial Forecast

HTD Earnings Forecast

Next quarter’s earnings estimate for HTD is €0.57 with a range of €0.07 to €0.90. The previous quarter’s EPS was €0.31. HTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.01% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Sales Forecast

Next quarter’s sales forecast for HTD is €270.92M with a range of €234.00M to €305.57M. The previous quarter’s sales results were €223.63M. HTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.25% of the time in the same period. In the last calendar year HTD has Performed in-line its overall industry.

HTD Stock Forecast FAQ

What is DE:HTD’s average 12-month price target, according to analysts?

Based on analyst ratings, Corcept Therapeutics’s 12-month average price target is 107.04.

What is DE:HTD’s upside potential, based on the analysts’ average price target?

Corcept Therapeutics has 29.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Corcept Therapeutics a Buy, Sell or Hold?

Corcept Therapeutics has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.

What is Corcept Therapeutics’s share price target?

The average share price target for Corcept Therapeutics is 107.04. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €144.06 ,and the lowest forecast is €43.65. The average share price target represents 29.18% Increase from the current price of €82.86.

What do analysts say about Corcept Therapeutics?

Corcept Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Corcept Therapeutics?

To buy shares of DE:HTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Corcept Therapeutics (HTD) Stock Forecast & Price Target

HTD Analyst Ratings

HTD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Corcept Therapeutics

HTD Analyst Recommendation Trends

HTD Financial Forecast

HTD Earnings Forecast

HTD Sales Forecast

HTD Stock Forecast FAQ

Detailed List of Analyst Forecasts